The estimated Net Worth of Matthew Call is at least $1.5 Million dollars as of 28 March 2023. Mr Call owns over 40,226 units of iTeos Therapeutics stock worth over $1,501,429 and over the last 4 years he sold ITOS stock worth over $0.
Mr has made over 2 trades of the iTeos Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 40,226 units of ITOS stock worth $118,667 on 28 March 2023.
The largest trade he's ever made was exercising 53,672 units of iTeos Therapeutics stock on 30 July 2021 worth over $158,332. On average, Mr trades about 11,737 units every 76 days since 2021. As of 28 March 2023 he still owns at least 93,898 units of iTeos Therapeutics stock.
You can see the complete history of Mr Call stock trades at the bottom of the page.
Matthew A. Call M.B.A. is the Chief Operating Officer at iTeos Therapeutics.
Mr A is 48, he's been the Chief Operating Officer of iTeos Therapeutics since . There are 3 older and 1 younger executives at iTeos Therapeutics. The oldest executive at iTeos Therapeutics, Inc. is Dr. Michel Detheux Ph.D., 55, who is the Pres, CEO & Director.
Matthew's mailing address filed with the SEC is C/O ITEOS THERAPEUTICS, INC., 321 ARSENAL STREET, WATERTOWN, MA, 02472.
Over the last 4 years, insiders at iTeos Therapeutics have traded over $196,492,023 worth of iTeos Therapeutics stock and bought 4,975,000 units worth $95,182,800 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Kol..., and Aaron I. Davis. On average, iTeos Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $1,817,279. The most recent stock trade was executed by Matthew Gall on 12 October 2023, trading 5,000 units of ITOS stock currently worth $41,850.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
iTeos Therapeutics executives and other stock owners filed with the SEC include: